96 related articles for article (PubMed ID: 3079198)
1. Effectiveness of short-term sulodexide treatment on peripheral vascular disease clinical manifestations.
Caramelli L; Mirchioni R; Carini A
Riv Eur Sci Med Farmacol; 1988 Feb; 10(1):55-8. PubMed ID: 3079198
[No Abstract] [Full Text] [Related]
2. Preliminary results of sulodexide treatment in patients with peripheral arteriosclerosis and hyperlipidemia. A multicentre trial.
Crepaldi G; Fellin R; Calabrò A; Baiocchi MR; Rossi A; Lenzi S; Descovich GC; Delmonte G; Gaddi A; Ventura A
Monogr Atheroscler; 1986; 14():215-21. PubMed ID: 3526129
[No Abstract] [Full Text] [Related]
3. [The significance of sulodexide in the prevention of obliterative atherosclerotic arterial disease of the lower limbs].
Martino R; Benini D
Clin Ter; 1985 Mar; 112(5):429-37. PubMed ID: 4017468
[No Abstract] [Full Text] [Related]
4. [Effectiveness and tolerability of heparan sulfate in the treatment of superficial thrombophlebitis. Controlled clinical study vs sulodexide].
Messa G; La Placa G; Puccetti L; Di Perri T
Minerva Cardioangiol; 1997 Apr; 45(4):147-53. PubMed ID: 9213829
[TBL] [Abstract][Full Text] [Related]
5. [Pattern of blood viscosimetric values, fibrinogen, and various glycoproteins in patients with obliterating sclerotic peripheral vascular disease treated with 3GS].
Sarno A; Bruno S; Romano A; Catania A; la Bruzzo S; Francavilla G; Caimi G
Clin Ter; 1980 Nov; 95(3):289-95. PubMed ID: 7214844
[No Abstract] [Full Text] [Related]
6. Sulodexide in the treatment of chronic venous disease.
Andreozzi GM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):73-81. PubMed ID: 22329592
[TBL] [Abstract][Full Text] [Related]
7. [Sulodexide in the therapy of vasculopathies].
Postiglione F; Pisani P; Gisonni P; Perrotta P; Gisonni A; Canciello M; Napolitano L; Brighina G; Ragno I; Salzano A
Clin Ter; 1986 May; 117(3):223-31. PubMed ID: 3524974
[No Abstract] [Full Text] [Related]
8. [Sulodexide treatment approach in patients with atherosclerotic vascular disease with various localizations].
Capone-Braga M; Tellini L; Boncompagni L; Bettoni M; Burali A; Bensi A
Clin Ter; 1987 Jan; 120(1):25-31. PubMed ID: 2973852
[No Abstract] [Full Text] [Related]
9. [Controlled study of the effect of sulodexide on peripheral diabetic macroangiopathy].
Piva I; Lora L; Baso A; Erle G
G Clin Med; 1985; 66(1-2):37-45. PubMed ID: 3891485
[No Abstract] [Full Text] [Related]
10. The effectiveness of glycosaminoglycans in peripheral vascular disease therapy: a clinical and experimental trial.
Corsi C; Bocci L; Cipriani C; Gazzini A; Marrapodi E
J Int Med Res; 1985; 13(1):40-7. PubMed ID: 3884410
[TBL] [Abstract][Full Text] [Related]
11. Treatment of vascular inner ear disease with pentoxifylline: a 4-week, controlled, randomized trial.
Incandela L; Cesarone MR; Belcaro G; De Sanctis MT; Nicolaides AN; Griffin M; Geroulakos G; Ramaswami G
Angiology; 2002; 53 Suppl 1():S19-22. PubMed ID: 11865830
[TBL] [Abstract][Full Text] [Related]
12. [Secondary prevention of coronary heart disease with lipid lowering drugs. Evaluating outcome eliminates the controversy].
Pedersen TR
Internist (Berl); 1995 Dec; 36(12):1174-8. PubMed ID: 8567223
[No Abstract] [Full Text] [Related]
13. Treatment of vascular inner ear disease in vascular patients with pentoxifylline: a controlled, randomized trial.
Cesarone MR; Incandela L; Belcaro G; De Sanctis MT; Nicolaides AN; Griffin M; Geroulakos G; Ramaswami G
Angiology; 2002; 53 Suppl 1():S23-6. PubMed ID: 11865831
[TBL] [Abstract][Full Text] [Related]
14. [Effect of sulodexide on hemorheological parameters in a group of patients with peripheral arteriosclerotic vascular disease].
Calabrò A; Rossi A; Baiocchi MR; Coscetti G; Fellin R; Crepaldi G
Ric Clin Lab; 1985; 15 Suppl 1():455-63. PubMed ID: 4035227
[TBL] [Abstract][Full Text] [Related]
15. Hemorheology and tissue oxygenation in hypertensives with lipoidoproteinosis and peripheral occlusive arterial disease (POAD) treated with sulodexide and pravastatine and evaluated with laser assisted optical rotational red cell analyzer (LORCA) and transcutaneous oxymetry.
Cicco G; Stingi GD; Vicenti P; Tarallo MS; Pirrelli A
Minerva Cardioangiol; 1999 Oct; 47(10):351-9. PubMed ID: 10670256
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of a sulfomucopolysaccharide (3GS) in the treatment of hyperlipoproteinemias].
Palmieri G; Perego M; Nazzari M; Casalini F
Clin Ter; 1982 Jun; 101(6):603-14. PubMed ID: 7128029
[No Abstract] [Full Text] [Related]
17. Effects of short-term treatment with coenzyme A or sulodexide on plasma lipids in patients with hypertriglyceridemia (type IV) or mixed hyperlipemia (type IIb).
Ghidini O; Zenari L; Guilarte N; Tessari R; Tomba A
Int J Clin Pharmacol Ther Toxicol; 1986 Jul; 24(7):390-6. PubMed ID: 3525431
[TBL] [Abstract][Full Text] [Related]
18. [Experience with sulodexide (Vessel Due F) in diabetics with ischemic disease of the lower extremities].
Utratová J; Mayer J; Elbl L; Vorlícek J; Prásek J
Vnitr Lek; 1993 Jun; 39(6):575-80. PubMed ID: 8212613
[TBL] [Abstract][Full Text] [Related]
19. [Necessity of hypolipemic treatment in patients with coronary disease].
Fernández-Miranda C; Aranda IL
Med Clin (Barc); 1999 Mar; 112(11):438. PubMed ID: 10231779
[No Abstract] [Full Text] [Related]
20. Sulodexide: a renewed interest in this glycosaminoglycan.
Lauver DA; Lucchesi BR
Cardiovasc Drug Rev; 2006; 24(3-4):214-26. PubMed ID: 17214598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
